Restoring Health & Mobility
Aziyo Biologics, Inc. was created by HighCape Partners with the mission of restoring health and mobility to the greatest number of patients. Our vision is to impact healthcare through innovation of new solutions realizing the commercial potential of regenerative medicine. Aziyo is built on long-standing corporate partners and deep product development and biologics processing expertise.
At Aziyo, we have witnessed first-hand that a transplanted ligament can enable mobility, a bone spinal implant can ease chronic pain, and a skin graft can bring much-needed relief to a burn victim.
These life-changing solutions fuel our utmost respect for the gift of donation and drive our dedication to scientific and operational excellence.
Interim President and Chief Executive Officer
Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Andrew M. Green
Chief Business Officer
Darryl Roberts, Ph.D.
Sr. VP, Operations and General Manager, Richmond
Vice President of Cardiovascular Sales
Vice President of Orthopedic Sales
Dana Yoo, Ph.D.
VP, Research & Development
VP, Technical Services
11.15.17 Aziyo Presents Positive Initial Data from Clinical Study of Biologic Extracellular Matrix Scaffold for Femoral Arterial Reconstruction
SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced positive results from PERFORM, a prospective, post-market study conducted in patients undergoing femoral arterial reconstruction using the company’s biologic extracellular matrix (ECM) scaffold. There were no device-related adverse events or infections and primary patency was maintained in 97.6% of procedures. The…Read More
11.03.17 Aziyo Launches CanGaroo Bio Envelope for Subcutaneous Implantable Cardioverter-Defibrillators
SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced the launch of a new CanGaroo Bio Envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). This is the only cardiac implantable electronic device (CIED) envelope available for use with S-ICDs. CanGaroo is a natural extracellular matrix (ECM) scaffold that is…Read More
SILVER SPRING, MD. – Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced completion of patient enrollment in SECURE, a prospective post market study of 1,000 patients treated with CanGaroo® ECM® Envelope in conjunction with cardiac implantable electronic device (CIED) placement. The CanGaroo ECM Envelope is intended to securely hold a CIED to…Read More
Commercial portfolio expanded with acquisition of CorMatrix® productsRead More
11.05.15 HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics
HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo BiologicsRead More